drug

BMS-986497

Phase 1updated 3mo ago

by Bristol-Myers Squibb Co

Phase 1

community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying BMS-986497

phase1Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromerecruitingn=105

News(0)

no news has mentioned this drug yet

Data sources

ClinicalTrials.gov

last refreshed 16m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug

save

BMS-986497

Phase 1updated 3mo ago

by Bristol-Myers Squibb Co

Phase 1

community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying BMS-986497

phase1Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromerecruitingn=105

News(0)

no news has mentioned this drug yet

Data sources

ClinicalTrials.gov

last refreshed 16m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

BMS-986497

all catalysts(0)

Trials studying BMS-986497

News(0)

Report a data issue

comments(0)

BMS-986497

all catalysts(0)

Trials studying BMS-986497

News(0)

Report a data issue

comments(0)